Asunercept
Clinical Efficacy in Two Indications
Our lead immuno-oncology candidate asunercept is in clinical development for the treatment of a variety of solid tumors and malignant hematological diseases. It has demonstrated statistically significant efficacy in a controlled phase II proof-of-concept trial in recurrent glioblastoma. Patients with a certain biomarker experienced the greatest benefit from treatment with asunercept. Apogenix is developing a companion diagnostic test based on this biomarker, so asunercept can be used as a personalized therapy.
Technology
The Apogenix team has created the HERA-ligand technology platform for the development of novel receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear advantages over other biologics such as antibodies and have the potential for broad application in oncology.
News
September 19, 2019
Publication in Human Vaccines & Immunotherapeutics Illustrates the Advantages of Hexavalent CD40 Agonists in Targeting CD40 in Immuno-Oncology
September 2, 2019
Publication in Cancer Management and Research Underlines the Potential of Apogenix’ Asunercept for the Treatment of Other Malignancies Beyond Glioblastoma and MDS